1.14× to 0.63× Debt-to-Equity: Can UPL Sustain Its Balance-Sheet Repair While Funding Growth?
UPL has made significant progress in reducing its debt burden while simultaneously improving profitability. With further growth investments planned, the key question is whether the company can continue repairing its balance sheet without slowing its expansion. This article examines the trade-off between deleveraging, capex, and working-capital requirements.
UPL was trading at around ₹539 per share, with a market capitalization of roughly ₹42,347 crore. The stock’s 52-week range was approximately ₹498–₹812, while its P/E was around 21x.
Debt Has Fallen Sharply
UPL’s balance-sheet repair has been substantial. Value research data shows debt-to-equity declining from 1.14× in FY24 to 0.81× in FY25 and 0.63× in FY26. On a TTM basis, the ratio had further declined to 0.45× by September 2026.
Also Read: 10 Stocks to Buy for an Upside of Up to 31%; Recommended by Macquarie
The reduction has also been supported by actual debt repayment rather than only changes in the ratio. In FY26, UPL reported gross debt of about $2.3 billion, down $850 million from FY24, while net debt declined to around $1.6 billion. Net debt-to-EBITDA improved to below 1.6× from 2.1× in FY25. This means stronger earnings have worked alongside lower borrowings to improve the company's leverage profile.
Earnings Are Supporting Deleveraging
The FY26 improvement was not simply a debt-cutting exercise. UPL reported ₹51,839 crore of revenue and ₹9,588 crore of EBITDA, with EBITDA growing faster than revenue. Contribution margin also expanded by 220 basis points during the year.
The improvement has continued into FY27. Q1 revenue increased 10% to ₹10,181 crore, while EBITDA rose 15% to ₹1,500 crore. EBITDA margin improved to 14.7% from 14.1%, marking the seventh consecutive quarter of revenue and EBITDA growth.
UPL also reported a positive PATMI (Profit After Tax and Minority Interest ) of ₹10 crore versus a loss of ₹88 crore in Q1 FY26. Management attributed the improvement partly to higher EBITDA, lower net finance cost, and a favorable exchange difference.
Growth Capex Will Test the Balance Sheet
The next stage is more complicated because UPL is not stopping investment to reduce debt. FY26 capex was about $261 million, while management has indicated a higher $325–350 million FY27 capex range. At the same time, management remains committed to keeping net debt-to-EBITDA below roughly 1.5× over the medium term.
That creates the central funding question. Growth investments can strengthen future earnings, but they also consume cash that could otherwise accelerate debt repayment. UPL therefore needs operating cash flow to expand sufficiently to fund both priorities.
The company's broader strategy includes continued investment in seeds, speciality chemicals, innovation and new products. In Q1, Advanta revenue increased 26%, while SUPERFORM grew 14%, with specialty chemicals revenue up 51%.
Working Capital Is the Key Pressure Point
The biggest near-term challenge is that leverage is improving even while working capital is absorbing cash. UPL's net working capital reached 110 days in Q1 FY27, up about 24 days YoY. Inventory days increased by around 13 days and receivable days by roughly 12 days. Management attributed this to lower Q1 crop-protection volumes, higher replacement input costs, seasonal inventory preparation, and delayed demand in India and Europe.
The balance sheet shows the impact clearly. Working capital increased from ₹8,119 crore in March 2026 to ₹15,941 crore in June 2026, while short-term debt utilization also increased because of the seasonal requirement.
Importantly, UPL has not indicated a structural deterioration in collections. It continues to use non-recourse receivables factoring as a risk-management measure, with around ₹6,755 crore of receivables factored as of June 2026.
Deleveraging Has Further to Go
The company is still reducing gross debt even under this pressure. In Q1 FY27, UPL reduced gross debt by more than $100 million, from $3.1 billion to $3.0 billion, despite the seasonal working-capital build-up and planned capex. Net debt-to-EBITDA improved to 2.4× from 2.6×, while net debt-to-equity remained around 0.6×.
There is also evidence that lower debt is improving the earnings structure. Q1 net finance cost declined 2% YoY, and management specifically cited lower finance costs as one factor behind the improvement in operating PATMI.
However, the balance-sheet repair cannot be measured only through falling debt ratios. With higher capex planned and working capital currently elevated, future cash generation will determine how quickly UPL can continue deleveraging.
Also Read: ESDS Software Shares Crash 26% in 5 Days: Is This Profit Booking or a Growth Concern?
Conclusion
UPL has made substantial progress in repairing its balance sheet, with debt-to-equity falling from 1.14× in FY24 to 0.63× in FY26 and 0.45× on a TTM basis. The next phase is less straightforward. UPL wants to continue investing in growth while also reducing leverage, and Q1 FY27 showed how seasonal working-capital requirements can absorb significant capital.
The key indicators to monitor are therefore EBITDA growth, working-capital days, operating cash generation and net debt-to-EBITDA. Together, they will show whether UPL can continue strengthening its balance sheet without slowing the investment required to support its next phase of growth.